Dashboard
Manage Tickers

ALLO


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

allogene-therapeutics-awarded-15m-grant-from-california-institute-for-regenerative-medicine-to-advance-development-of-allogeneic-car-t-in-renal-cell-carcinoma
Allogene Therapeutics Awarded $15M Grant F...
04/26/2024 12:35:19

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic ...

to-the-moon-a-look-inside-an-etf-focused-on-companies-at-the-cutting-edge-of-innovation
To The Moon! A Look Inside An ETF Focused ...
04/18/2024 18:29:09

hc-wainwright--co-reiterates-buy-on-allogene-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Allo...
03/19/2024 10:55:34

HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $10 pri...

rbc-capital-reiterates-outperform-on-allogene-therapeutics-maintains-10-price-target
RBC Capital Reiterates Outperform on Allog...
03/15/2024 16:19:26

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.

recap-allogene-therapeutics-q4-earnings
Recap: Allogene Therapeutics Q4 Earnings
03/14/2024 20:20:07

allogene-therapeutics-q4-2023-gaap-eps-051-misses-046-estimate-sales-21000k-miss-23571k-estimate
Allogene Therapeutics Q4 2023 GAAP EPS $(0...
03/14/2024 20:17:47

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate ...

earnings-scheduled-for-march-14-2024
Earnings Scheduled For March 14, 2024
03/14/2024 09:52:13

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

allogene-therapeutics-earnings-preview
Allogene Therapeutics Earnings Preview
03/13/2024 18:01:35

allogene-therapeutics-and-arbor-biotechnologies-announce-global-gene-editing-licensing-agreement-to-support-advancement-of-next-generation-allogeneic-car-t-platform-in-autoimmune-disease
Allogene Therapeutics And Arbor Biotechnol...
03/12/2024 12:57:01

Allogene's AlloCAR T™ Autoimmune Disease Platform Leverages Arbor's CRISPR Gene-Editing Technology First Allogeneic CAR...

jp-morgan-maintains-overweight-on-allogene-therapeutics-lowers-price-target-to-8
JP Morgan Maintains Overweight on Allogene...
02/27/2024 18:18:22

JP Morgan analyst Brian Cheng maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and lowers the price target fr...

allogene-therapeutics-to-restate-previously-filed-financial-statements-related-to-the-december-2020-formation-of-the-allogene-overland-biopharm-joint-venture-in-asia-no-impact-on-cash-cash-equivalents-and-marketable-investments-cash-runway-or-business-operations
Allogene Therapeutics To Restate Previousl...
02/16/2024 13:33:13

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business Operations Company Targeting On or Befo...

cymabay-therapeutics-contextlogic-snap-and-other-big-stocks-moving-higher-on-monday
CymaBay Therapeutics, ContextLogic, Snap A...
02/12/2024 15:22:57

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ...

hc-wainwright--co-maintains-buy-on-allogene-therapeutics-lowers-price-target-to-10
HC Wainwright & Co. Maintains Buy on Allog...
01/19/2024 11:38:56

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price t...

cell-therapy-focused-allogene-therapeutics-resource-prioritization-a-bold-move-says-analyst
Cell Therapy Focused Allogene Therapeutics...
01/05/2024 19:32:52

Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND ...

why-applied-therapeutics-shares-are-trading-lower-by-over-35-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Applied Therapeutics Shares Are Tradin...
01/05/2024 18:13:57

Shares of Applied Therapeutics, Inc.

guggenheim-downgrades-allogene-therapeutics-to-neutral
Guggenheim Downgrades Allogene Therapeutic...
01/05/2024 14:36:17

Guggenheim analyst Michael Schmidt downgrades Allogene Therapeutics (NASDAQ:ALLO) from Buy to Neutral.

jmp-securities-downgrades-allogene-therapeutics-to-market-perform
JMP Securities Downgrades Allogene Therape...
01/05/2024 11:26:58

JMP Securities analyst Reni Benjamin downgrades Allogene Therapeutics (NASDAQ:ALLO) from Market Outperform to Market Perform.

franklin-covey-shares-fall-after-q1-results-joins-theravance-biopharma-voyager-therapeutics-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Franklin Covey Shares Fall After Q1 Result...
01/05/2024 11:19:39

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
01/04/2024 21:31:07

allogene-therapeutics-partners-with-foresight-diagnostics-to-develop-mrd-based-in-vitro-diagnostic-for-use-in-alpha3-for-frontline-consolidation-in-large-b-cell-lymphoma
Allogene Therapeutics Partners With Foresi...
01/04/2024 21:18:20

Partnership Will Utilize Foresight's Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene's A...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION